grant

Directed evolution of TCRs with improved antigen sensitivity

Organization MASSACHUSETTS INSTITUTE OF TECHNOLOGYLocation CAMBRIDGE, UNITED STATESPosted 18 Jul 2025Deadline 30 Jun 2027
NIHUS FederalResearch GrantFY2025AddressAffinityAmino Acid ReceptorsAntigen PresentationAntigen TargetingAntigensAutoantigensAutologous AntigensAutomobile DrivingBindingBiologyCD3CD3 AntigensCD3 ComplexCD3 moleculeCancer PatientCategoriesCell BodyCell Communication and SignalingCell SignalingCellsClinicClinical TrialsClosure by LigationComplexConstant RegionCryo-electron MicroscopyCryoelectron MicroscopyDNA mutationDirected Molecular EvolutionDisadvantagedElectron CryomicroscopyEngineeringGenetic ChangeGenetic defectGenetic mutationHeterograftHeterologous TransplantationHistocompatibility ComplexHistocompatibility ComplicesIg Constant RegionImmuneImmune mediated therapyImmunesImmunoglobulin Constant RegionImmunologically Directed TherapyImmunotherapyIn VitroIn vivo analysisIntracellular Communication and SignalingInvestigatorsLibrariesLigationLytotoxicityMHC ReceptorMajor Histocompatibility ComplexMajor Histocompatibility Complex ReceptorMajor Histocompatibility ComplicesMalignant CellMature T-CellMature T-LymphocyteMediatorModificationMolecular InteractionMutateMutationOKT3 antigenPatientsPeptidesPhenotypePhosphorylationPositionPositioning AttributeProcessProductionProliferatingProtein PhosphorylationPublishingReceptor ProteinReceptor SignalingResearch PersonnelResearch ResourcesResearchersResourcesRiskSafetySelf-AntigensSignal TransductionSignal Transduction SystemsSignalingSpeedStructureT cell based immune therapyT cell based therapeuticsT cell based therapyT cell directed therapiesT cell immune therapyT cell immunotherapyT cell receptor based immunotherapyT cell receptor cellular immunotherapyT cell receptor engineered therapyT cell receptor immunotherapyT cell responseT cell targeted therapeuticsT cell therapyT cell treatmentT cell-based immunotherapyT cell-based treatmentT cellular immunotherapyT cellular therapyT lymphocyte based immunotherapyT lymphocyte based therapyT lymphocyte therapeuticT lymphocyte treatmentT-Cell ActivationT-Cell Antigen ReceptorsT-Cell DevelopmentT-Cell OntogenyT-Cell ReceptorT-Cell Receptor InteractionT-Cell Receptor TherapyT-Cell Receptor TreatmentT-Cell Receptor based TherapyT-Cell Receptor based TreatmentT-CellsT-LymphocyteT-Lymphocyte DevelopmentT-cell therapeuticsT-cell transfer therapyT3 AntigensT3 ComplexT3 moleculeTCR ActivationTCR InteractionTCR T cell immunotherapyTCR T cell therapyTCR TherapyTCR based T cell immunotherapyTCR based TherapyTCR based immune therapyTCR based immunotherapyTCR based treatmentTCR immunotherapyTestingTherapeuticTimeToxic effectToxicitiesTranslatingTreatment EfficacyTreatment-related toxicityTumor AntigensTumor-Associated AntigenValidationVariantVariationWorkXenograftXenograft procedureXenotransplantationactivate T cellsadoptive T cell transferadoptive T lymphocyte transferadoptive T-cell therapybiological signal transductioncancer antigenscancer cellcell transformationcell typecross reactivitycryo-EMcryoEMcryogenic electron microscopycytokinecytotoxicitydesigndesign and constructdesign and constructiondesigningdirected evolutiondrivingengineered T cellsgenetically engineered T-cellsgenome mutationimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunogenimprovedin vivo evaluationin vivo testinginnovateinnovationinnovativeintervention efficacymouse modelmurine modelnovelreceptorresponsetherapeutic T-cell platformtherapeutic efficacytherapeutic outcometherapeutic toxicitytherapy associated toxicitytherapy efficacytherapy outcometherapy related toxicitytherapy toxicitythymus derived lymphocytetransformed cellstransgenic T- cellstreatment toxicitytreatment-associated toxicitytumortumor-specific antigenvalidationsxeno-transplantxeno-transplantation
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

Project Summary
T cells express T cell receptors (TCRs), which recognize antigens presented as peptides displayed by major

histocompatibility complexes (pMHC). Recognition of pMHC antigens activates the T cell, enabling immune

effector functions leading to the clearance of infected or transformed cells. TCR-T cell therapies are an

engineered immunotherapy that take advantage of this biology to engineer T cells to express a tumor-specific

TCR to redirect T cell responses against cancer cells. These therapies have achieved objective responses for

some cancer patients in clinical trials but have also suffered from limitations in efficacy and toxicity.

Since TCRs against many classes of tumor antigens are naturally low affinity, the TCRs used for these therapies

often require affinity maturation to achieve efficacy. Unfortunately, this process can also increase the affinity for

off-target peptides on healthy cells. Several clinical trial patients have suffered fatal toxicities as a result. Further,

affinity maturation is labor intensive, and the resulting mutations are only applicable to one TCR. Cancer antigens

are highly diverse, so it is limiting to repeat this process for every new antigen.

We propose a new TCR engineering strategy that we hypothesize will address these limitations. We will

implement high throughout library screens of TCR constant region variants to select for mutations that improve

TCR signaling strength. Because these modifications are not in the TCR antigen recognition domains, they have

the potential to improve efficacy without introducing cross-reactivity. Further, they could be applicable to all

TCRs, regardless of their targets, which would eliminate the need to re-engineer the TCR for each different

antigen. Together, these approaches could identify efficacious, safe, and broadly applicable TCRs as candidates

for TCR-T cell therapies.

Grant Number: 1R21CA305319-01
NIH Institute/Center: NIH

Principal Investigator: Michael Birnbaum

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →